 
                    
                    <![CDATA[Clinical Implications Remain After Dasatinib CRL in CML/ALL]]>
The oncology community has been closely tracking the development of an amorphous, lower-dose formulation of dasatinib (Dasynoc) under the HyNap technology, especially given the ongoing focus on optimizing adherence and long-term tolerability in chronic …
 
             
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                   
           
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                    